Rakuten Investment Management Inc. Buys New Shares in IQVIA Holdings Inc. $IQV

Rakuten Investment Management Inc. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 109,872 shares of the medical research company’s stock, valued at approximately $20,869,000. Rakuten Investment Management Inc. owned 0.06% of IQVIA as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of the company. Alliancebernstein L.P. increased its holdings in IQVIA by 0.6% in the 2nd quarter. Alliancebernstein L.P. now owns 3,555,929 shares of the medical research company’s stock worth $560,379,000 after buying an additional 19,573 shares during the period. Artisan Partners Limited Partnership purchased a new stake in shares of IQVIA in the 2nd quarter valued at $515,772,000. JPMorgan Chase & Co. increased its stake in shares of IQVIA by 22.8% in the second quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after acquiring an additional 581,157 shares during the period. Nordea Investment Management AB lifted its position in IQVIA by 12.3% during the third quarter. Nordea Investment Management AB now owns 2,314,219 shares of the medical research company’s stock valued at $421,257,000 after purchasing an additional 253,759 shares during the period. Finally, Lazard Asset Management LLC grew its position in IQVIA by 6.1% during the 2nd quarter. Lazard Asset Management LLC now owns 1,866,537 shares of the medical research company’s stock worth $294,145,000 after purchasing an additional 107,500 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on IQV. Robert W. Baird set a $258.00 target price on IQVIA and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. Hsbc Global Res raised shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Truist Financial increased their price target on shares of IQVIA from $265.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Finally, UBS Group increased their target price on shares of IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $249.19.

IQVIA Trading Down 1.7%

IQV stock opened at $233.76 on Wednesday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The business’s 50-day moving average is $228.10 and its 200 day moving average is $204.62. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock has a market cap of $39.81 billion, a price-to-earnings ratio of 32.07, a PEG ratio of 2.42 and a beta of 1.36.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter last year, the business posted $2.84 earnings per share. The business’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.